NCT06861036|Not Yet Recruiting
Heterogeneity of Oral Squamous Cell Carcinoma Analysis by Single Cell RNA Sequencing
HOASIS
Loading search results
HOASIS
Sponsor study identifier
interventional
50
1 country
1
Study Start
May 15, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
May 15, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
May 15, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of this project is to characterise the heterogeneity of all cell populations (tumour cells, stromal and immune microenvironment) present in the tumor and their normal (and leucoplasic) counterparts by scRNAseq in OSCC patients.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 15, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 24, 2025
Actual (reported)March 6, 2025
Actual (reported)May 15, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
May 15, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
May 15, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Characterization of the heterogeneity of all cell populations (tumour cells, stromal and immune microenvironment) present in the tumor and their normal (and leucoplasic) counterparts by scRNAseq in OSCC patients.
Transcriptomic data from scRNAseq for all cell populations
3 years
Description of the functional interactions among tumor, stromal, and immune subpopulations identified by scRNAseq
3 years
Correlation between refined patient stratification (based on tumor, stromal and immune sub-population) and the impact on the response to ex-vivo treatments.
3 years
Identification of prognostic and predictive biomarkers for oral squamous cell carcinoma evolution
3 years
A clinical-biological cohort of 50 patients with OSCC. Blood sample and biospecimen at the time of a standard surgery.
* 1 or 2 tumoral specimen (depending on the size of the tumor) * 1 specimen of the healthy oral mucosa * 1 leucoplakia specimen if applicable. The biospecimens will be collected at the time of the surgery organised for the standard routine medical care.
Blood sampling (6 mL), taken from a routine biological exam.
Centre Léon Bérard
Lyon, 69008, France
Philippe Zrounba, M.D.
philippe.zrounba@lyon.unicancer.fr
First Submitted
February 24, 2025
First Posted
March 6, 2025
Study Start
May 15, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
May 15, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
May 15, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
March 6, 2025
Record last verified: 2025-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: